NCT07595146

Brief Summary

The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
21mo left

Started Aug 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 19, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2028

Last Updated

July 24, 2026

Status Verified

July 1, 2026

Enrollment Period

1.6 years

First QC Date

May 12, 2026

Last Update Submit

July 22, 2026

Conditions

Outcome Measures

Primary Outcomes (8)

  • Feasibility to accrue HSCT patient/caregiver dyads

    Percentage of eligible caregivers approached who consent and enroll within 24 months.

    2 years

  • MCP-Dyad intervention completion

    Percentage of patients and caregivers in the MCP-Dyad cohort who complete at least 5 out of 7 intervention sessions (benchmark: 70%).

    End of treatment (approximately 14 weeks)

  • MCP-Dyad Feasibility rating from participants (Feasibility of Intervention Measure-FIM)

    Percentage of patients and caregivers who rate MCP-Dyad as 4/5 or higher on the Feasibility of Intervention Measure (FIM) 4-item questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention feasibility.

    End of treatment (approximately 14 weeks)

  • MCP-Dyad retention

    Percentage of randomized dyads with both members completing follow-up assessments (benchmark: 75%).

    End of treatment (approximately 14 weeks)

  • MCP-Dyad intervention fidelity and protocol delivery

    Percentage of audited sessions meeting intervention fidelity standards and delivered per protocol based on fidelity assessments (benchmark: ≥80%)

    End of treatment (approximately 14 weeks)

  • MCP-Dyad acceptability as rated on the Acceptability of Intervention Measure (AIM)

    Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Acceptability of Intervention Measure (AIM) questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention acceptability.

    End of treatment (approximately 14 weeks)

  • MCP-Dyad appropriateness as rated on the Intervention Appropriateness Measure (IAM)

    Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Intervention Appropriateness Measure (IAM) questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention appropriateness.

    End of treatment (approximately 14 weeks)

  • MCP-Dyad dyad-level retention outreach

    Percentage of missed sessions or assessments that receive outreach within 2 days (benchmark: ≥85%).

    End of treatment (approximately 14 weeks)

Secondary Outcomes (12)

  • Change in survivor and caregiver health-related quality of life.

    Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention

  • Change in survivor and caregiver existential distress

    Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention

  • Change in survivor and caregiver spiritual well-being

    Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention

  • Change in Benefit Finding Scale (BFS) score

    Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention

  • Change in survivor and caregiver mutuality (quality of relationship)

    Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention

  • +7 more secondary outcomes

Study Arms (2)

Meaning-Centered Psychotherapy (MCP) Dyad

EXPERIMENTAL

The MCP-Dyad arm participants will meet with an MCP-Dyad interventionist to engage in didactic content, reflection, and discussion to teach participants how to apply four sources of meaning to their lives

Behavioral: Meaning-Centered Psychotherapy

Usual Care

ACTIVE COMPARATOR

The standard of care arm will receive standard resources and consultations for HSCT care, which include a joint educational class for patients and caregivers before and after treatment.

Behavioral: Usual Care

Interventions

Survivor and caregiver dyads will participate in a seven-session, telehealth delivered Meaning-Centered Psychotherapy for Dyads (MCP-Dyad) program post-transplant.

Meaning-Centered Psychotherapy (MCP) Dyad
Usual CareBEHAVIORAL

Survivor and caregiver dyads will receive standard resources and consultations for hematopoietic stem cell transplantation (HSCT) care, which include a joint educational class for patients and caregivers before and after treatment.

Usual Care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Eligible patients and their caregivers must be adults (≥18 years)
  • Patient must have undergone HSCT for a malignant blood cancer condition
  • Caregiver must be the main support person (e.g., signed caregiving contract) for the HSCT patient
  • Both the patient and their caregiver must be willing to participate in the study (dyads only)
  • Be able to read, write, and speak in English
  • Have access to a smartphone, computer, or tablet necessary for study participation and assessments. If a patient/caregiver dyad is interested in participating but does not have such a device, we will provide a Tracfone with smartphone capabilities for each member of the dyad

You may not qualify if:

  • Patients undergoing HSCT for nonmalignant conditions
  • Patients and caregivers with severe cognitive or psychiatric impairment that may affect informed consent/participation
  • Prisoners, pregnant women, and institutionalized persons
  • Patients with severe cognitive or psychiatric impairment that would affect informed consent or participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Study Officials

  • Natalie McAndrew, PhD, RN

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 12, 2026

First Posted

May 19, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

February 28, 2028

Study Completion (Estimated)

April 30, 2028

Last Updated

July 24, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations